Pricing Log in Create free account
Saturday 17 October 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.09
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — 1 — — 1 — — — —
Insider Ownership 3.72%

Capital & Financial Ratios $m

Market Cap 20,930.00
Revenue 14,737.30
Net Income (410.70)
Free Cash Flow 1,890.60
Net Debt 12,464.80
Current Ratio 1.58 (at or above 1.5: strong)
Debt/Equity 0.94
P/E ratio 0.00
Fwd P/E 61.10 (above 35: high)
P/S ratio 1.47
P/B ratio 1.52
Past 5Y EPS Growth —
This Y EPS Growth 7.21%
Next Y EPS Growth 6.69%
Next Y revenue growth 3.43%
Next 5Y EPS Growth 6.91%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.3×, against a ten-year median of 2.1×; over the ten years it ranged from 1.7× in 2020 to 3.5× in 2016.
P/S against its own 10 years 75.01%
10-year low 10-year high
P/B against its own 10 years 77.96%
10-year low 10-year high
EV/Sales against its own 10 years 59.90%
10-year low 10-year high
EV/FCF against its own 10 years 52.75%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate 0.48
Annual Dividend Yield 2.57%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 0.51
0.12
0.12
0.12
2025 0.48
0.12
0.12
0.12
0.12
2024 0.48
0.12
0.12
0.12
0.12
2023 0.48
0.12
0.12
0.12
0.12
2022 0.48
0.12
0.12
0.12
0.12
2021 0.33
0.11
0.11
0.11
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 992 735 1,322 887
Receivables 3,700 3,221 3,031 3,126
Inventory 3,470 3,854 3,999 3,933
Other 2,786 — — —
12,976 9,521 9,789 10,056
2023 2024 2025 Q'26
Payables 1,938 1,854 1,754 1,727
ST’ Debt 1,943 8 1,933 1,739
Other 3,669 3,725 3,283 2,880
7,777 5,779 7,094 6,346

Compound Annual Growth %

10y 5y 3y
Sales 4.25% 3.66% (4.20%)
Cash Flow 1.43% 13.46% (8.26%)
Earnings 0.00% 0.00% 0.00%
Book Value 4.18% (8.51%) (11.29%)

Revenue $m

Mar Jun Sep Dec Year
’26 3,517 3,757 — — —
’25 3,254 3,582 3,760 3,704 14,300
’24 3,663 3,797 3,751 3,528 14,739
’23 3,729 3,919 3,942 3,837 15,427
’22 4,192 4,117 4,078 3,876 16,263
’21 4,430 4,578 4,537 4,342 17,886
’20 2,619 2,731 2,972 3,624 11,946
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 388 382 — — —
’25 536 220 745 816 2,316
’24 615 379 827 483 2,303
’23 971 525 835 569 2,900
’22 1,139 803 869 189 2,999
’21 849 559 1,086 523 3,017
’20 291 380 525 36 1,232
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 268 336 — — —
’25 485 167 646 640 1,939
’24 805 747 2,574 339 4,466
’23 889 449 781 684 2,804
’22 1,072 721 754 24 2,570
’21 808 543 967 207 2,526
’20 181 327 467 (422) 553
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.15 (0.10) — — —
’25 (2.55) 0.00 (0.11) (0.30) (3.00)
’24 0.09 (0.27) 0.08 (0.43) (0.53)
’23 0.19 0.22 0.27 (0.64) 0.05
’22 0.33 0.26 0.29 0.83 1.71
’21 (0.86) (0.23) 0.26 (0.22) (1.05)
’20 0.04 0.08 0.36 (1.59) (1.11)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 33.60 29.39 26.03 16.63 12.75 11.96 8.42 8.74 9.93 6.85

Analyst estimates 2026–2028

Powerpack
High 54.44 45.87 47.82 32.23 23.11 18.77 15.60 12.40 13.62 12.62
People
People Employees 35,000 35,000 35,000 35,000 45,000 37,000 37,000 38,000 32,000 30,000
Revenue/emp, $m 0.32 0.34 0.33 0.33 0.27 0.48 0.44 0.41 0.46 0.48
Income, $m
Income, $m Revenue 11,077 11,908 11,434 11,501 11,946 17,886 16,263 15,427 14,739 14,300
Gross margin, % 42.40 40.17 35.00 33.89 31.78 31.17 39.95 41.74 38.15 35.06
EBT 122 903 298 154 (721) (664) 2,813 203 (623) (3,665)
EBT margin, % 1.10 7.58 2.61 1.34 (6.04) (3.71) 17.30 1.32 (4.23) (25.63)
Net income 480 696 353 17 (670) (1,269) 2,079 55 (634) (3,515)
Depreciation 1,523 1,806 2,110 2,019 2,216 4,507 3,028 3,321 3,214 5,735
Per share, $
Per share, $ Revenue 21.59 22.28 22.22 22.30 19.87 14.80 13.42 12.85 12.35 12.21
Earnings 0.94 1.30 0.69 0.03 (1.11) (1.05) 1.71 0.05 (0.53) (3.00)
Cash flow 3.99 3.86 4.55 3.50 2.05 2.50 2.47 2.42 1.93 1.98
Capex (1.46) (1.51) (2.27) (0.73) (1.13) (0.41) (0.35) (0.08) 1.81 (0.32)
Free cash flow 2.53 2.35 2.28 2.76 0.92 2.09 2.12 2.34 3.74 1.66
Book value 21.67 24.90 23.65 23.04 38.18 16.95 17.39 17.05 15.62 12.57
Shares, m 513 535 515 516 601 1,209 1,212 1,200 1,193 1,171
Valuation, ×
Valuation, × P/E 42.98 32.91 40.29 670.00 0.00 0.00 6.66 227.80 0.00 0.00
P/S 1.81 1.94 1.23 0.90 0.94 0.91 0.85 0.89 1.01 1.02
P/B 1.80 1.73 1.16 0.87 0.49 0.80 0.65 0.67 0.80 0.99
EV/Sales 3.25 3.25 2.41 2.05 3.24 2.17 1.96 2.00 2.04 1.93
EV/FCF 27.74 30.83 23.46 16.53 70.10 15.34 12.38 10.99 6.74 14.27
Cash, $m
Cash, $m Operating cash flow 2,047 2,065 2,342 1,804 1,232 3,017 2,999 2,900 2,303 2,316
Capex (751) (809) (1,166) (378) (679) (491) (429) (96) 2,163 (377)
Free cash flow 1,297 1,255 1,175 1,426 553 2,526 2,570 2,804 4,466 1,939
Balance, $m
Balance, $m Working capital 2,482 828 1,780 1,188 2,305 1,019 3,889 5,199 3,741 2,695
Total debt 16,898 15,956 13,863 13,683 28,322 23,088 19,274 18,132 15,986 16,429
Net debt 15,899 15,664 13,475 13,208 27,477 22,386 18,014 17,140 15,252 15,106
Shareholders’ equity 11,118 13,308 12,167 11,884 22,954 20,493 21,072 20,467 18,636 14,711
Returns, %
Returns, % ROA 1.68 1.97 1.03 0.05 (1.44) (2.18) 3.96 0.11 (1.42) (8.93)
ROIC 1.62 3.10 2.21 1.78 (0.26) (0.05) 2.58 1.27 0.02 (5.58)
ROE 4.60 5.70 2.77 0.14 (3.85) (5.84) 10.00 0.26 (3.24) (21.08)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Viatris Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TAK Takeda Pharmaceutical Co. $61.9B 29.6× — +1.71% (above 0%: growing) −4.35% (below 0%: shrinking) −95.56% (below 0%: shrinking) 66.66% 16.51% Compare
TEVA Teva Pharmaceutical Industries Ltd. $47.9B 65.9× 30.7× −0.81% (below 0%: shrinking) n/m +121.43% (above 0%: growing) 51.98% (2.03%) Compare
HLN Haleon PLC Sponsored ADR $43.7B 22.6× 17.6× −0.32% (below 0%: shrinking) +40.00% (above 0%: growing) −42.94% (below 0%: shrinking) 62.88% 25.36% Compare
ZTS Zoetis Inc. $32.4B 13.0× 12.3× −0.24% (below 0%: shrinking) +2.48% (above 0%: growing) +17.43% (above 0%: growing) 72.73% 37.56% Compare
UTHR United Therapeutics Corporation $23.2B 17.6× 20.1× −1.92% (below 0%: shrinking) +13.99% (above 0%: growing) +58.76% (above 0%: growing) 87.30% 42.23% Compare
VTRS Viatris Inc. $20.9B — (loss-making) 61.1× +4.88% (above 0%: growing) n/m +101.08% (above 0%: growing) 38.77% 0.17%
NBIX Neurocrine Biosciences, Inc. $13.9B 19.2× 30.5× +39.49% (above 0%: growing) +31.19% (above 0%: growing) +43.69% (above 0%: growing) 97.58% 15.80% Compare
ELAN Elanco Animal Health Incorporated $11.8B — (loss-making) 278× +10.23% (above 0%: growing) +450.00% (above 0%: growing) +35.56% (above 0%: growing) 58.33% 7.97% Compare
RDY Dr. Reddy's Laboratories Ltd $10.7B 32.9× 24.3× −14.44% (below 0%: shrinking) −70.00% (below 0%: shrinking) −143.40% (below 0%: shrinking) 46.54% 4.81% Compare
Median of peers $27.8B 22.6× 24.3× −0.28% +13.99% +26.50% 64.77% 16.16%

All 86 Drug Manufacturers Specialty & Generic stocks →

VTRS metrics, ten years each

Viatris Inc. (VTRS) key facts

  • Concern: Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.
  • Viatris Inc. (VTRS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, VTRS traded at $18.66, a market capitalization of $20.9 billion.
  • Viatris Inc. pays an annual dividend of $0.48 per share, a yield of 2.57%.
  • Return on equity was −21.1% and debt-to-equity 0.94.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.61 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Viatris Inc. (VTRS) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/VTRS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com